GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Median PS Value

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Median PS Value : $16.20 (As of May. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $3.255. Swedish Orphan Biovitrum AB's 10-Year median PS Ratio is 4.977. Therefore, the Median PS Value for today is $16.20.

As of today (2024-05-11), Swedish Orphan Biovitrum AB's share price is $13.475. Swedish Orphan Biovitrum AB's Median PS Value is $16.20. Therefore, Swedish Orphan Biovitrum AB's Price to Median PS Value for today is 0.83.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Median PS Value or its related term are showing as below:

SWOBY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48   Med: 0.61   Max: 0.94
Current: 0.83

During the past 13 years, the highest Price to Median PS Value of Swedish Orphan Biovitrum AB was 0.94. The lowest was 0.48. And the median was 0.61.

SWOBY's Price-to-Median-PS-Value is ranked better than
52.87% of 505 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs SWOBY: 0.83

Swedish Orphan Biovitrum AB Median PS Value Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Median PS Value Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 18.22

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 18.22 16.40

Competitive Comparison of Swedish Orphan Biovitrum AB's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value falls into.



Swedish Orphan Biovitrum AB Median PS Value Calculation

Swedish Orphan Biovitrum AB's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=3.255*4.977
=16.20

10-Year Median PS Ratio is 4.977.
Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.255.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Swedish Orphan Biovitrum AB's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=13.475/16.20
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB Median PS Value Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).